DRUG CHANNEL LANDSCAPE Q4 2022
Drug channel sales declined in Q4 2022 versus the prior quarter, and the channel lost overall share in the total MULOC market amid that market’s 8.6% Q4 growth. This softness was led by a 4.7% decline in the health department. But the news is not all bad, as the channel is lapping outstanding 2021 performance and flu season now has consumers looking to the channel for remedies — despite inflation concerns that continue to dampen overall spending.
How can we help you supercharge growth and profitability?
95% of CPG, retail, and health and beauty companies in the Fortune 100 work with us.
Copyright 2022 IRI. All Rights Reserved.